HYFT
BEARISH
$1.07
Live
MindWalk Holdings Corp. · NASDAQ
Target $4.0
(+273.8%)
$0.4
52W Range
$3.25
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 11, 2026
Market cap
$49.98M
P/E
N/A
ROE
-58.8%
Profit margin
-43.6%
Debt/Equity
0.24
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
MindWalk Holdings Corp. (HYFT) exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness in fundamental health. While the company shows strong top-line revenue growth of 52.4% and maintains a healthy current ratio of 3.74, it is unable to translate this growth into profitability, with an operating margin of -88.36%. The stock is currently in a sharp technical downtrend, losing over 40% of its value in the last six months. Despite a high analyst target price of $4.00, the consistent failure to meet earnings estimates (0/4 beats) suggests a significant disconnect between analyst expectations and operational reality.
Key Strengths
Strong YoY revenue growth of 52.40%
Healthy liquidity with a current ratio of 3.74
Low leverage with a Debt/Equity ratio of 0.24
Positive gross margin of 57.19%
Strong short-term Q/Q revenue growth (52.42%)
Key Risks
Critical financial health (Piotroski F-Score 1/9)
Severe lack of profitability with ROE at -58.82%
Consistent earnings misses (Average surprise -106.63% over last 4 quarters)
Strong bearish technical trend (0/100 score)
Micro-cap volatility and low analyst coverage (only 2 analysts)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
23
Weak
30
50
20
15
0
AI Verdict
High-Risk Speculative
Key drivers: Piotroski F-Score of 1/9, Negative operating margins, Bearish price action, Strong revenue growth
Confidence
90%
Value
30/100
Valuation is speculative as P/E and PEG are N/A
Positives
- Price/Sales ratio of 1.78 is relatively low for biotech
Watchpoints
- Price/Book of 4.68 is high for a non-profitable entity
- No Graham Number available due to lack of earnings
Future
50/100
Growth is present but inefficient
Positives
- Consistent revenue growth >50%
- High analyst target price ($4.00)
Watchpoints
- Inability to scale revenue into profit
- Negative EPS progression
Past
20/100
Long-term value destruction despite short-term volatility
Positives
- 1Y return of +166.8% (likely speculative spike)
Watchpoints
- 5Y change of -91.3%
- Consistent failure to meet earnings estimates
Health
15/100
Liquidity is the only saving grace in a failing fundamental profile
Positives
- Low Debt/Equity
- Strong Current Ratio
Watchpoints
- Piotroski F-Score 1/9
- Negative ROA and ROE
Dividend
0/100
Non-dividend paying growth/speculative stock
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.07
Analyst Target
$4.0
Upside/Downside
+273.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HYFT and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HYFT
MindWalk Holdings Corp.
Primary
|
-91.3% | -62.5% | +166.8% | -40.9% | -16.4% | -6.1% |
|
ELUT
Elutia Inc.
Peer
|
-91.4% | -20.8% | -53.7% | +28.2% | -2.6% | +4.6% |
|
ALGS
Aligos Therapeutics, Inc.
Peer
|
-98.8% | -77.7% | -26.4% | -25.8% | +1.5% | +8.4% |
|
BTMD
biote Corp.
Peer
|
-85.2% | -74.7% | -54.1% | -47.5% | -16.8% | +10.4% |
|
ARAY
Accuray Incorporated
Peer
|
-93.2% | -87.0% | -78.7% | -76.4% | -27.4% | -24.4% |
HYF
MindWalk Holdings Corp.
Primary
5Y
-91.3%
3Y
-62.5%
1Y
+166.8%
6M
-40.9%
1M
-16.4%
1W
-6.1%
ELU
Elutia Inc.
Peer
5Y
-91.4%
3Y
-20.8%
1Y
-53.7%
6M
+28.2%
1M
-2.6%
1W
+4.6%
ALG
Aligos Therapeutics, Inc.
Peer
5Y
-98.8%
3Y
-77.7%
1Y
-26.4%
6M
-25.8%
1M
+1.5%
1W
+8.4%
BTM
biote Corp.
Peer
5Y
-85.2%
3Y
-74.7%
1Y
-54.1%
6M
-47.5%
1M
-16.8%
1W
+10.4%
ARA
Accuray Incorporated
Peer
5Y
-93.2%
3Y
-87.0%
1Y
-78.7%
6M
-76.4%
1M
-27.4%
1W
-24.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
4.68
P/S Ratio
1.78
EV/Revenue
1.52
EV/EBITDA
-4.06
Market Cap
$49.98M
Profitability
Profit margins and return metrics
Profit Margin
-43.6%
Operating Margin
-88.36%
Gross Margin
57.19%
ROE
-58.82%
ROA
-18.94%
Growth
Revenue and earnings growth rates
Revenue Growth
+52.4%
Earnings Growth
N/A
Q/Q Revenue Growth
+52.42%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.24
Low debt
Current Ratio
3.74
Strong
Quick Ratio
3.4
Excellent
Cash/Share
$0.28
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q1 2026
Revenue
$0.0B
Gross Margin
59.3%
Op. Margin
-88.0%
Net Margin
-94.5%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.55x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-07-14
$N/A
2026-03-12
$-0.06
-63.4% surprise
2025-12-15
$-0.05
-238.5% surprise
2025-09-15
$-0.05
-17.9% surprise
Healthcare Sector Comparison
Comparing HYFT against 226 companies in the Healthcare sector
(19 bullish, 76 neutral, 131 bearish)
Return on Equity (ROE)
-58.82%
This Stock
vs
-40.43%
Sector Avg
+45.5%
(Excellent)
Profit Margin
-43.6%
This Stock
vs
-18.65%
Sector Avg
+133.8%
(Superior)
Debt to Equity
0.24
This Stock
vs
4.61
Sector Avg
-94.9%
(Less Debt)
Revenue Growth
52.4%
This Stock
vs
97.21%
Sector Avg
-46.1%
(Slower)
Current Ratio
3.74
This Stock
vs
3.51
Sector Avg
+6.6%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HYFT
MindWalk Holdings Corp.
|
BEARISH | $49.98M | - | -58.8% | -43.6% | $1.07 | |
|
ELUT
Elutia Inc.
|
BULLISH | $48.77M | - | -% | 434.2% | $1.14 | Compare |
|
ALGS
Aligos Therapeutics, Inc.
|
BEARISH | $46.58M | - | -196.9% | -% | $7.57 | Compare |
|
BTMD
biote Corp.
|
NEUTRAL | $55.53M | 2.01 | -% | 14.1% | $1.49 | Compare |
|
ARAY
Accuray Incorporated
|
BEARISH | $44.0M | - | -70.3% | -8.2% | $0.37 | Compare |
HYFT
MindWalk Holdings Corp.
BEARISH
Mkt Cap
$50M
P/E
-
ROE
-58.8%
Price
$1.07
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-27 | Areglado (Richard Scott) | Senior Officer of Issuer | Acquisition in the public market at price 1.12 per | 26,500 | $29,547 |
| 2026-03-19 | Lynch (Thomas) | Senior Officer of Issuer | Acquisition in the public market at price 1.16 per | 20,000 | $23,280 |
| 2026-03-18 | Brands (Ingrid Maria Henri) | Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | Acquisition in the public market at price 1.20 per | 6,000 | $7,212 |
| 2026-03-18 | Lynch (Thomas) | Senior Officer of Issuer | Acquisition in the public market at price 1.21 per | 20,000 | $24,200 |
| 2026-03-18 | Van Hyfte (Dirk Medard Helena) | Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | Acquisition in the public market at price 1.20 per | 6,000 | $7,212 |
| 2026-03-17 | Brands (Ingrid Maria Henri) | Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | Acquisition in the public market at price 1.23 per | 10,000 | $12,290 |
| 2026-03-17 | Van Hyfte (Dirk Medard Helena) | Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | Acquisition in the public market at price 1.23 per | 10,000 | $12,290 |
| 2026-03-16 | Brands (Ingrid Maria Henri) | Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | Acquisition in the public market at price 1.22 per | 14,000 | $17,122 |
| 2026-03-16 | Van Hyfte (Dirk Medard Helena) | Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6) | Acquisition in the public market at price 1.22 per | 14,000 | $17,122 |
| 2026-01-28 | Lieber Jonathan C | Director of Issuer | Stock Award | 7,807 | - |
| 2025-10-20 | Areglado (Richard Scott) | Senior Officer of Issuer | Stock Award | - | - |
| 2025-10-20 | Lynch (Thomas) | Senior Officer of Issuer | Stock Award | - | - |
Areglado (Richard Scott)
Senior Officer of Issuer
2026-03-27
26,500 shares
·
$29,547
Lynch (Thomas)
Senior Officer of Issuer
2026-03-19
20,000 shares
·
$23,280
Brands (Ingrid Maria Henri)
Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
2026-03-18
6,000 shares
·
$7,212
Lynch (Thomas)
Senior Officer of Issuer
2026-03-18
20,000 shares
·
$24,200
Van Hyfte (Dirk Medard Helena)
Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
2026-03-18
6,000 shares
·
$7,212
Brands (Ingrid Maria Henri)
Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
2026-03-17
10,000 shares
·
$12,290
Van Hyfte (Dirk Medard Helena)
Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
2026-03-17
10,000 shares
·
$12,290
Brands (Ingrid Maria Henri)
Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
2026-03-16
14,000 shares
·
$17,122
Van Hyfte (Dirk Medard Helena)
Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
2026-03-16
14,000 shares
·
$17,122
Lieber Jonathan C
Director of Issuer
2026-01-28
7,807 shares
Areglado (Richard Scott)
Senior Officer of Issuer
2025-10-20
Lynch (Thomas)
Senior Officer of Issuer
2025-10-20
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning HYFT from our newsroom.
Newest → oldest
No matching news yet.